Tolerability of the oral fluoropyrimidine S-1 after hand-foot syndrome-related discontinuation of capecitabine in western cancer patients

References

• Twelves C, Gollins S, Samuel L, et al. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17:239–245.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13:566–575.
   PubMed Web of Science ®Google Scholar
• Tebbutt NC, Wilson K, Gebski VJ, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010;28:3191–3198.
   PubMed Web of Science ®Google Scholar
• Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 1996;7:548–557.
   PubMed Web of Science ®Google Scholar
• Yen-Revollo JL, Goldberg RM, McLeod HL. Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res. 2008;14:8–13.
   PubMed Web of Science ®Google Scholar
• Muro K, Boku N, Sugihara K, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomized phase 2/3 non-inferiority study (FIRIS Study) Lancet Oncol. 2010;11:853–860.
   Google Scholar
• Ajani JA, Buyse M, Lichinitser M, et al. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. Eur J Cancer. 2013;49:3616–3624.
   PubMed Web of Science ®Google Scholar
• Hong YS, Park YS, Lee JW, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol. 2012;13:1125–1132.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol. 2013;14:1278–1286.
   PubMed Web of Science ®Google Scholar
• Kwakman JJ, Punt CJ. Oral drugs in the treatment of metastatic colorectal cancer. Expert Opin Pharmacother. 2016;17:1351–1361.
   PubMed Web of Science ®Google Scholar
• Punt CJ, Simkens LH, Van Rooijen JM, et al. Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): the SALTO study of the Dutch Colorectal Cancer Group. J Clin Oncol. 2016;34:(suppl; abstr 3640).
   PubMed Web of Science ®Google Scholar
• Abushullaih S, Saad ED, Munsell M, et al. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest. 2002;20:3–10.
   PubMed Web of Science ®Google Scholar
• Zhu AX, Clark JW, Ryan DP, et al. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. Cancer Chemother Pharmacol. 2007;59:285–293.
   PubMed Web of Science ®Google Scholar
• van Groeningen CJ, Peters FJ, Schornagel JH, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol. 2000;18:2772–2779.
   PubMed Web of Science ®Google Scholar
• Chung KY, Saito K, Zergebel C, et al. Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. Oncology. 2011;81:65–72.
   PubMed Web of Science ®Google Scholar
• Twelves C, Scheithauer W, McKendrick J, et al. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23:1190–1197.
   PubMed Web of Science ®Google Scholar